Boston Scientific Announces Agreement to Acquire Valencia Technologies Corporation

Rhea-AI Summary

Boston Scientific (NYSE: BSX) agreed to acquire Valencia Technologies to add the eCoin implantable tibial nerve stimulation (ITNS) system for urge urinary incontinence (UUI). The eCoin device is FDA-approved (2022) and showed a 68% responder rate (>=50% UUI reduction) in the pivotal trial. Boston Scientific said the deal is expected to close in H1 2026, will expand its urology and pelvic health portfolio, and aims to broaden minimally invasive treatment options for overactive bladder. The company expects an immaterial impact on adjusted EPS in 2026 but greater GAAP dilution from acquisition-related charges and amortization; transaction terms were not disclosed.

Positive

• eCoin FDA approval in 2022
• 68% pivotal-trial responder rate (>=50% UUI reduction)
• Acquisition expands BSX into implantable tibial nerve stimulation

Negative

• Deal will be more dilutive on a GAAP basis due to charges and amortization
• Specific financial terms were not disclosed

News Market Reaction

-1.97%

1 alert

-1.97% News Effect

On the day this news was published, BSX declined 1.97%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

OAB patient population: nearly 30 million adults OAB treatment rate: approximately 19% eCoin responder rate: 68% +5 more

8 metrics

OAB patient population nearly 30 million adults U.S. adults ages 40+ with bothersome OAB symptoms

OAB treatment rate approximately 19% Rate of OAB treatment beyond behavioral and lifestyle adjustments

eCoin responder rate 68% Patients with at least 50% reduction in UUI episodes in pivotal trial

UUI reduction threshold 50% reduction Criterion for response in eCoin pivotal clinical trial

eCoin FDA approval year 2022 Year the eCoin system was approved by the U.S. FDA

Expected close timing first half of 2026 Targeted completion window for Valencia Technologies acquisition

Current share price $97.64 Price before publication of the Valencia acquisition news

Market capitalization $144,745,640,688 Equity value prior to the acquisition announcement

Market Reality Check

Price: $93.53 Vol: Volume 9,725,629 is 12% a...

normal vol

$93.53 Last Close

Volume Volume 9,725,629 is 12% above the 20-day average of 8,680,946 shares. normal

Technical Price $97.64 is trading below the 200-day MA at $100.81 ahead of the deal.

Peers on Argus

BSX is down 0.75% with key peers also modestly lower (e.g., MDT -1.44%, PHG -1.2...

BSX is down 0.75% with key peers also modestly lower (e.g., MDT -1.44%, PHG -1.2%, ABT -0.4%, SYK -0.12%, EW -0.17%), but no peers appeared on the momentum scanner and sector momentum was not flagged.

Historical Context

5 past events · Latest: Jan 02 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 02	Conference participation	Neutral	-0.7%	Announced J.P. Morgan Healthcare Conference appearance and Q4/FY25 results call scheduling.
Dec 10	Partner product update	Neutral	+0.2%	CathVision board change and ECGenius System Version 3.5 commercial release noted with BSX link.
Nov 03	Investor conferences	Neutral	-2.1%	Outlined participation in Wolfe and Citi healthcare conferences with webcast access details.
Oct 22	Earnings report	Positive	+4.0%	Q3 2025 sales and EPS beat guidance with strong Cardiovascular and MedSurg growth.
Oct 17	Acquisition announcement	Positive	+1.5%	Agreed to acquire Nalu Medical, expanding neuromodulation with FDA‑cleared PNS system.

Pattern Detected

Recent BSX news, including acquisitions and earnings, has generally seen price moves that align directionally with the news tone, with positive fundamental updates followed by positive reactions.

Recent Company History

Over the past few months, Boston Scientific reported strong Q3 2025 results with net sales of $5.065B and above-guidance EPS, and announced the Nalu Medical acquisition to expand neuromodulation. Earlier, it outlined a busy investor conference schedule and upcoming earnings call. These events, alongside the prior Nalu acquisition, frame today’s Valencia Technologies agreement as another portfolio-expansion step within an active strategic period.

Market Pulse Summary

This announcement adds the FDA‑approved eCoin ITNS system for overactive bladder and urge urinary in...

Analysis

This announcement adds the FDA‑approved eCoin ITNS system for overactive bladder and urge urinary incontinence to Boston Scientific’s urology portfolio. Prior acquisitions in neuromodulation and interventional cardiology suggest a continued focus on targeted therapy-area expansion. The company notes an immaterial impact on adjusted EPS in 2026 but GAAP dilution from deal costs. Investors may watch closing progress, clinical adoption of eCoin, and upcoming 2025 earnings updates for additional context.

Key Terms

overactive bladder, urge urinary incontinence, implantable tibial nerve stimulation, percutaneous tibial nerve stimulation, +4 more

8 terms

overactive bladder medical

"In the United States, nearly 30 million adults ages 40 and older have bothersome symptoms of OAB."

A condition where the bladder sends urgent, frequent signals to urinate, sometimes causing leakage; think of it like a doorbell that rings too often or unexpectedly. It matters to investors because treatments and devices that reduce these symptoms can create steady, growing markets for drugs, medical devices and care services, and regulatory approvals or clinical trial results can quickly affect a company’s sales outlook and stock value.

urge urinary incontinence medical

"device for the treatment of urge urinary incontinence (UUI), a common symptom of overactive bladder"

A chronic bladder condition where a person experiences sudden, strong urges to urinate and may leak urine before reaching a bathroom; likened to a faulty alarm system that triggers too often. It matters to investors because prevalence, treatment options, and regulation drive demand for drugs, devices, and diagnostics, affecting companies’ sales forecasts, clinical trial value, and potential market size.

implantable tibial nerve stimulation medical

"eCoin® System is an implantable tibial nerve stimulation (ITNS) device for the treatment"

An implantable tibial nerve stimulation system is a small medical device placed near the ankle that sends mild electrical pulses to the tibial nerve to help control bladder function, often used for overactive bladder and urinary incontinence. Investors care because it represents a durable medical-device market with potential for steady revenue from device sales, follow-up procedures and therapy management, and its commercial success depends on clinical effectiveness, regulatory approval and insurance reimbursement — think of it as a pacemaker for bladder nerves.

percutaneous tibial nerve stimulation medical

"intended for patients who have undergone a successful trial of percutaneous tibial nerve stimulation (PTNS)"

A minimally invasive therapy that uses a thin needle near the ankle to send mild electrical pulses along the tibial nerve to retrain bladder control, commonly used for overactive bladder and urinary incontinence. It matters to investors because clinical effectiveness, reimbursement rules, and patient adoption determine demand for the devices, clinic services, and related follow-on treatments — much like a new fuel-efficient engine can change car sales and service needs.

tibial nerve medical

"device intermittently and automatically stimulates the tibial nerve to help regulate"

A major nerve running down the back of the lower leg that carries signals for movement and feeling to the calf, foot and toes—like the main wiring harness for the lower leg. Investors care because injuries, diseases or treatments affecting the tibial nerve can create demand for medical devices, drugs, surgeries and rehabilitation, influence clinical trial results and safety data, and shape regulatory approvals and reimbursement decisions.

u.s. food and drug administration regulatory

"The eCoin system, approved by the U.S. Food and Drug Administration in 2022, is a coin-sized device"

The U.S. Food and Drug Administration is the federal agency that evaluates and enforces safety, effectiveness and labeling standards for medicines, medical devices, vaccines, food and related products before they reach consumers. For investors it matters because FDA approvals, warnings or recalls determine whether a product can be sold, how quickly it reaches the market and how costly compliance will be—changes that directly affect a company’s revenue, costs and stock value.

adjusted earnings per share financial

"expected to have an immaterial impact on adjusted earnings per share in 2026"

Adjusted Earnings Per Share shows how much profit a company makes for each share of stock, but it removes unusual or one-time items like big expenses or gains. This helps investors see the company's true ongoing performance, making it easier to compare how well different companies are doing over time.

gaap financial

"expected to be more dilutive on a GAAP basis due to acquisition-related net charges"

GAAP, or Generally Accepted Accounting Principles, are a set of standardized rules and guidelines that companies follow when preparing their financial statements. They ensure consistency, transparency, and comparability across different companies, making it easier for investors to understand and compare financial information accurately. This helps investors make informed decisions based on trustworthy and uniform financial reports.

AI-generated analysis. Not financial advice.

Acquisition to expand urology offerings for people living with overactive bladder

MARLBOROUGH, Mass., Jan. 12, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it has entered into a definitive agreement to acquire Valencia Technologies Corporation, a privately held medical technology company focused on the development and commercialization of innovative solutions to treat bladder dysfunction. The company's eCoin® System is an implantable tibial nerve stimulation (ITNS) device for the treatment of urge urinary incontinence (UUI), a common symptom of overactive bladder (OAB).

In the United States, nearly 30 million adults ages 40 and older have bothersome symptoms of OAB.¹ The condition can have a significant impact on quality of life, mental health, sleep, productivity and social activities.² One study found that the overall treatment rate for OAB, beyond behavioral and lifestyle adjustments, was approximately 19%.³

The eCoin system, approved by the U.S. Food and Drug Administration in 2022, is a coin-sized device that is placed under the skin, near the ankle, during a minimally invasive procedure. The device is intended for patients who have undergone a successful trial of percutaneous tibial nerve stimulation (PTNS) or for patients who are intolerant to or have an inadequate response to more conservative UUI treatments. Once implanted, the device intermittently and automatically stimulates the tibial nerve to help regulate how the brain communicates with the bladder. In the eCoin pivotal clinical trial, 68% of patients responded with at least a 50% reduction in UUI episodes.⁴

"The addition of the eCoin system to the Boston Scientific portfolio will enable us to expand into implantable tibial nerve stimulation (ITNS), a high-growth adjacency for our Urology business," said Meghan Scanlon, senior vice president and president, Urology, Boston Scientific. "ITNS technology complements our existing pelvic health product line, and we look forward to offering a more comprehensive set of treatment options to patients across the care continuum."

Boston Scientific expects to complete the acquisition in the first half of 2026, subject to customary closing conditions. The transaction is expected to have an immaterial impact on adjusted earnings per share in 2026 and is expected to be more dilutive on a GAAP basis due to acquisition-related net charges and amortization expense. Specific terms of the transaction have not been disclosed.

About Boston Scientific 
Boston Scientific transforms lives through innovative medical technologies that improve the health of patients around the world. As a global medical technology leader for more than 45 years, we advance science for life by providing a broad range of high-performance solutions that address unmet patient needs and reduce the cost of healthcare. Our portfolio of devices and therapies helps physicians diagnose and treat complex cardiovascular, respiratory, digestive, oncological, neurological and urological diseases and conditions. Learn more at www.bostonscientific.com and follow us on LinkedIn. 

Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "may," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding our business plans, the financial and business impact of the transaction and the anticipated benefits of the transaction, the closing of the transaction and the timing thereof, and product performance and impact. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Risks and uncertainties that may cause such differences include, among other things: economic conditions, including the impact of foreign currency fluctuations; future U.S. and global political, competitive, reimbursement and regulatory conditions, including changing trade and tariff policies; geopolitical events; manufacturing, distribution and supply chain disruptions and cost increases; disruptions caused by cybersecurity events; disruptions caused by public health emergencies or extreme weather or other climate change-related events; labor shortages and increases in labor costs; variations in outcomes of ongoing and future clinical trials and market studies; new product introductions; expected procedural volumes; the closing and integration of acquisitions, including our ability to achieve the anticipated benefits of the proposed transaction and successfully integrate Valencia Technologies' operations; business disruptions (including disruptions in relationships with employees, customers and suppliers) following the announcement and/or closing of the proposed transaction; demographic trends; intellectual property; litigation; financial market conditions; the execution and effect of our business strategy, including our cost-savings and growth initiatives; future business decisions made by us and our competitors; the conditions to the completion of the proposed transaction, including the receipt of any required regulatory approvals and clearances, may not be satisfied at all or in a timely manner; and the closing of the proposed transaction may not occur or may be delayed. These and any new risks and uncertainties, which may arise from time to time, are difficult to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A - Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements, except as required by law. This cautionary statement is applicable to all forward-looking statements contained in this press release.

CONTACTS: 
Nate Gilbraith 
Media Relations
+1 (701) 212-9589
nate.gilbraith@bsci.com

Lauren Tengler 
Investor Relations 
+1 (508) 683-4479 
BSXInvestorRelations@bsci.com

---

¹ Coyne, et al. "National community prevalence of overactive bladder in the United States stratified by sex and age." Urology. Volume 77, Issue 5, P1081-1087, MAY 2011. DOI: https://doi.org/10.1016/j.urology.2010.08.039

² Reynolds, et al. "The Burden of Overactive Bladder on US Public Health." Curr Bladder Dysfunct Rep, Mar 2016.

³ Mohamud H, et al. Trends in Overactive Bladder Therapy: Associations Between Clinical Care Pathways, Practice Guidelines, and Therapy Utilization Patterns. Neurourol Urodyn. 2025 Feb;44(2):319-329. doi: 10.1002/nau.25627.

⁴ Rogers A, et al. Pivotal study of leadless tibial nerve stimulation with eCoin ® for urgency urinary incontinence: an open-label, single arm trial. Journal of Urology. August 2021. DOI: https://doi.org/10.1097/JU.0000000000001733

View original content:https://www.prnewswire.com/news-releases/boston-scientific-announces-agreement-to-acquire-valencia-technologies-corporation-302658431.html

SOURCE Boston Scientific Corporation

FAQ

What did Boston Scientific (BSX) announce on January 12, 2026 about Valencia Technologies?

Boston Scientific announced a definitive agreement to acquire Valencia Technologies, maker of the eCoin ITNS system, with expected close in H1 2026.

How effective was Valencia's eCoin system in clinical trials mentioned in the BSX announcement?

The eCoin pivotal trial reported a 68% responder rate of patients achieving at least a 50% reduction in UUI episodes.

What is the expected 2026 EPS impact of the Valencia acquisition for BSX?

Boston Scientific expects an immaterial impact on adjusted EPS in 2026, but more GAAP dilution from acquisition-related charges and amortization.

When will Boston Scientific complete the acquisition of Valencia Technologies (BSX)?

The transaction is expected to be completed in the first half of 2026, subject to customary closing conditions.

What patient population does the eCoin ITNS device target according to the BSX release?

The eCoin system targets patients with urge urinary incontinence related to overactive bladder, typically adults aged 40 and older who responded to PTNS or failed conservative treatments.